A Study of N-Acetylcysteine (N-AC)in People Receiving CAR T-cell Therapy for Lymphoma
Lymphoma
About this trial
This is an interventional treatment trial for Lymphoma focused on measuring N-AC, N-Acetylcysteine, Lymphoma, CD19 CAR T-cell Therapy, 21-386, Memorial Sloan Kettering Cancer Center
Eligibility Criteria
Inclusion Criteria:
- Patients must be 18 years of age or older
- Patients who will receive axicabtagene ciloleucel for treatment of lymphoma
Patients must have adequate end organ function to be eligible for this study as defined by the following criteria:
- ECOG performance status 0-2
- Hematologic function with ANC ≥ 1000, Hgb ≥ 8, Plt ≥ 50k unless there is disease related hematologic toxicity
- Renal function with CrCr ≥ 40 ml/min or Cr ≤ 1.5 x ULN
- Hepatic function with ALT/AST ≤ 2.5 x ULN, TBili ≤ 1.5 x ULN.
Exclusion Criteria:
- Patients with known allergy to N-AC
Sites / Locations
- Memorial Sloan Kettering Cancer CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Participants with Lymphoma, Cohort 1
Participants with Lymphoma, Cohort 2
Participants with Lymphoma, Cohort 3
The first dose escalation cohort in the study will be treated at 25% of that target dose level
The second cohort in the study will be treated at 50% of that target dose level
The third cohort in the study will be treated at 100% of that target dose level only if no DLTs are seen at lower doses.